A 3-week Study Investigating Patient Use and Functionality of Formoterol in a Novel Inhalation Device in Patients With Asthma
- Conditions
- Asthma
- Registration Number
- NCT00130351
- Lead Sponsor
- Novartis
- Brief Summary
This study is designed to investigate the ability of patients with asthma to properly use a new multi-dose dry powder inhaler (MDDPI) device in a real-life situation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 155
- Patients who are capable of understanding the directions for device usage, evaluating device function and completing the patient diary
- Patients who have a current diagnosis of asthma
- Patients who have a documented forced expiratory volume at 1 second (FEV1) reversibility of at least 12% over baseline value following administration of a bronchodilator (i.e. "historical" reversibility) or demonstrate a >12% increase in FEV1 over their baseline value within 30 minutes after inhalation of up to 360 µg (4 puffs) of albuterol at Visit 1. The administration of albuterol for the reversibility test must be within 30 minutes after baseline spirometry.
- Patients who were enrolled in study CFOR258F2304 or CFOR258F2306, or who have any experience using the Certihaler® device.
- QTc above 450 milliseconds for males and 470 milliseconds for females, or any findings on the screening electrocardiogram (ECG) that in the opinion of the investigator would present a safety hazard for continuation in the study
- Patients who have a known history of untoward reactions to sympathomimetic amines or to inhaled medications or to any of the individual components in those therapies
- Other protocol-defined inclusion and exclusion criteria apply
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Device use: Patients were instructed to record the number appearing in the dose counter window after their dose on the diary card. Safety: Assessed by adverse events, physical examinations, vital signs abnormalities, forced expiratory volume in 1 second (FEV1) and screening ECG.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (11)
The Asthma & Allergy Center, PC
🇺🇸Papillion, Nebraska, United States
Allergy and Asthma Medical Group & Research Center
🇺🇸San Diego, California, United States
Clinical Research Institute
🇺🇸Minneapolis, Minnesota, United States
Allergy & Asthma Associates of Santa Clara Res. Center
🇺🇸San Jose, California, United States
Allergy and Asthma Specialists Medical Group and Research Ct
🇺🇸Huntington Beach, California, United States
Colorado Allergy and Asthma Centers, PC
🇺🇸Englewood, Colorado, United States
Northeast Medical Research Associates, Inc.
🇺🇸North Dartmouth, Massachusetts, United States
Northeast Medical Research Associates, Inc
🇺🇸North Dartmouth, Massachusetts, United States
North Carolina Clinical Research
🇺🇸Raleigh, North Carolina, United States
The Clinical Research Center
🇺🇸Saint Louis, Missouri, United States
Allergy Associates Research Center
🇺🇸Portland, Oregon, United States